ArticleNature communications2025
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active.
Celia Sequera et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it